News
New HIV Vaccine Could Cost As Little As Sh2,225 Per Year For Patients: Research
Drug cost 1,000 times less than current price, research suggests
A new “vaccine-like” HIV drug could cost as little as $40 (Sh4,225) according to new research.
Lenacapavir, an antiretroviral drug developed by US pharmaceutical company, Gilead, currently costs $42,250 (Sh 5,519,166) for the first year for patients in the US, France, Norway and Australia.
The drug that is described as “the closest we have ever been to an HIV vaccine” could cost $40 (Sh4,225) annually for each patient, 1,000 times less than the current price, research suggests.
Early trials have shown that treatment offers full protection to more than 5,000 women in South Africa and Uganda, according to results announced last month by Gilead.
Lenacapavir is given by injection twice a year and can prevent infection and suppress HIV in those who are already infected.
The UN program, UNAIDS, said it could “herald a breakthrough for HIV prevention” if the drug was “rapidly and affordably” available.
There were 1.3 million new HIV infections last year, while 39 million people are living with the virus, according to the World Health Organization.
Kenya Insights allows guest blogging, if you want to be published on Kenya’s most authoritative and accurate blog, have an expose, news TIPS, story angles, human interest stories, drop us an email on [email protected] or via Telegram
-
Business2 weeks agoTHE HANDSHAKE THAT BECAME A NOOSE: How Tuju’s Alleged Intimate Access to EADB’s Yeda Apopo Produced a Sh294 Million Deal With No Written Contract, and Why That Trust Destroyed an Empire
-
Investigations6 days agoForged Legacy: How Kaplan and Stratton’s Peter Gachuhi Is Accused of Faking a Top AG’s Will as State Claims Damning Evidence
-
News1 week agoMen Linked to Akasha Drug Dynasty Charged With Death Threats and Assault at Nairobi Nightclub
-
News1 week agoCity Lawyer Kimani Wachira Caught Up In Bribery Web Fights Claims
-
Business6 days agoHow Firm Linked To Mombasa Tycoon Jaffer Was Allowed To Import Fuel At Bloated Price And Set To Make Billions In Profits From Iranian War Crisis In Kenya
-
News5 days agoTreasury Hands Sh358M Brief to Eric Gumbo’s Firm While Bypassing Standard Rules — and the Lawyer Is Already Deep Inside Ruto’s State Machine
-
Business5 days agoSold And Abandoned: How Diageo and Asahi Are Locking Kenya’s EABL Minority Shareholders Out Of East Africa’s Biggest Corporate Heist
-
Business6 days agoTHE BANK THAT BROKE THE TRUCKER: How NCBA’s Asset Financing Empire Is on Trial Before London’s Most Feared Arbitral Tribunal
